Vimarsana
Biggest News Aggregation in the World

Page 44 - Hematologic Malignancies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hematologic Malignancies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hematologic Malignancies Today - Breaking & Trending Today

Updated Data for Janssen's Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma - Vimarsana News

Updated Data for Janssen's Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Published: June 5, 2022

New teclistamab data presented at the 2022 ASCO Annual Meeting report longer follow-up from Phase 1/2 MajesTEC-1 study evaluating the BCMAxCD3 bispecific antibody, including progression-free survival and subgroup analyses1Data from MajesTEC-1 study published in The New England Journal of Medicine2BEERSE, Belgium--(B...

Source: pharmiweb.com
Related Topics:
United StatesJenni MildonYusri ElsayedEdmond Chan MbchMaria Victoria MateosNone Of The Janssen Pharmaceutical CompaniesAmerican Society Of Clinical OncologyEuropean CommissionDrug AdministrationCancer Research InstituteJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonEuropean Organisation For ResearchExchange CommissionUniversity Hospital Of SalamancaCompanies Of JohnsonEuropean Medicines AgencyAmerican Cancer SocietyNew England JournalClinical OncologyTriple Class Exposed Multiple MyelomaConfidence IntervalConsultant PhysicianUniversity Hospital
Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expan - Vimarsana News

Atara Biotherapeutics Announces First Clinical Data from Ongoing Tab-cel® European Multicenter Expan

Published: June 4, 2022

Overall Response Rate (ORR) of 60% Observed in Patients with Relapsed or Refractory (R/R) EBV+ PTLD Consistent with Previously Reported StudiesCompletion of All Pre-Approval Inspections Required to Support EU Marketing Authorization Application; Anticipated European Commission Approval On-Track for Q4 2022SOUTH SAN...

Source: pharmiweb.com
Related Topics:
Mccormick PlaceUnited StatesSouth San FranciscoThousand OaksEric HyllengrenRalf TrappeJakob DupontAtara Biotherapeutics IncAmerican Society Of Clinical OncologyMccormick Place Convention Center ChicagoEuropean CommissionEuropean Commission ApprovalHead Of Global Research Development At AtaraExchange CommissionEuropean Medicines AgencySecurities ExchangeAccess ProgramOverall Response RatePreviously ReportedAll Pre Approval Inspections RequiredAuthorization ApplicationAnticipated European Commission Approval On TrackExpanded Access ProgramClinical OncologyAnnual Meeting
Sarah Cannon to Present Latest Oncology Research Insights at 2022 ASCO® Annual Meeting - Vimarsana News

Sarah Cannon to Present Latest Oncology Research Insights at 2022 ASCO® Annual Meeting

Published: June 3, 2022

Press release content from Business Wire. The AP news staff was not involved in its creation.

Source: apnews.com
Related Topics:
United StatesLake NonaLake MaryUnited KingdomCesar Augusto PerezLowell HartSusanna UlahannanGerald FalchookRussell SchilderAndrew MckenzieManish PatelGemma SturgillHoward BurrisRebecca GelmanShekeab JauhariKathleen MooreMelissa JohnsonMeredith MckeanMeredith PelsterDavid SpigelLucio GordanWilliam Kevin KellyJeremy PantinCobolimab MonotherapySarah Cannon Development Innovations
Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual Meeting - Vimarsana News

Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual Meeting

Published: June 3, 2022

-- 100% ORR at both dose levels; deep and durable responses observed in patients with poor prognostic factors -- -- 22 of 31 (71%) evaluable patients reached...

Source: prnewswire.com
Related Topics:
United StatesMccormick PlaceLaura MorganMyesha LacyMatthewj FrigaultCellular Therapy Service At MassInternational Myeloma Working GroupAmerican Society Of Clinical OncologyMccormick Place Convention CenterDrug AdministrationCancer CenterInstructor At Harvard Medical SchoolPrnewswire Arcellx IncSam Brown IncExchange CommissionArcellx IncSecurities ExchangeClinical OncologyAssistant DirectorCellular Therapy ServiceMass General Cancer CenterHarvard Medical SchoolRami ElghandourChief ExecutivePresentation Details
Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual Meeting - Vimarsana News

Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 2022 ASCO Annual Meeting

Published: June 3, 2022

-- 100% ORR at both dose levels; deep and durable responses observed in patients with poor prognostic factors -- -- 22 of 31 (71%) evaluable patients reached...

Source: prnewswire.com
Related Topics:
United StatesMccormick PlaceLaura MorganMyesha LacyMatthewj FrigaultCellular Therapy Service At MassInternational Myeloma Working GroupAmerican Society Of Clinical OncologyMccormick Place Convention CenterDrug AdministrationCancer CenterInstructor At Harvard Medical SchoolPrnewswire Arcellx IncSam Brown IncExchange CommissionArcellx IncSecurities ExchangeClinical OncologyAssistant DirectorCellular Therapy ServiceMass General Cancer CenterHarvard Medical SchoolRami ElghandourChief ExecutivePresentation Details